Melanotan II

Background

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of α-melanocyte‑stimulating hormone (α‑MSH), originally developed as a melanocortin receptor agonist to investigate pharmacologic skin pigmentation and sexual function.[15] It is structurally derived from the ACTH(4–10)/α‑MSH core sequence and incorporates N‑acetyl‑norleucine and D‑phenylalanine to enhance potency and stability.[11][12] The peptide sequence is commonly described as Ac‑Nle‑cyclo[Asp‑His‑D‑Phe‑Arg‑Trp‑Lys]‑NH₂, forming a lactam bridge between Asp and Lys side chains.[11][12]

Early work on melanocortin analogs in the 1980s–1990s at the University of Arizona focused on designing superpotent α‑MSH mimetics for photoprotective tanning, yielding the linear analog afamelanotide (NDP‑MSH) and later the cyclic analog MT‑II.[15] Afamelanotide proceeded into formal drug development and is approved in the EU and US (as a SC implant) for erythropoietic protoporphyria, whereas MT‑II remained an experimental tool compound and has not been approved for therapeutic use.[15]

Chemically, MT‑II is a cyclic peptide with improved resistance to enzymatic degradation compared with native α‑MSH, which contributes to greater in vivo half‑life and receptor potency.[11][12][13] It is often used in pharmacology as a prototypic non‑selective melanocortin receptor (MCR) agonist to probe melanocortin biology in pigmentation, energy homeostasis, sexual behavior, and stress response.[9][15]

Mechanism of action

Receptor pharmacology

Melanotan II acts as a high‑affinity agonist at several melanocortin receptor subtypes, particularly MC1R, MC3R, MC4R, and MC5R.[15] These receptors are class A G protein‑coupled receptors activated by endogenous melanocortins derived from proopiomelanocortin (POMC), including α‑MSH and ACTH.[15]

• MC1R (melanocortin 1 receptor): expressed primarily on melanocytes; activation stimulates eumelanin synthesis via cAMP signaling and upregulation of microphthalmia‑associated transcription factor (MITF) and tyrosinase, leading to increased skin pigmentation and photoprotection.[13][15]
• MC3R/MC4R: located in the hypothalamus and other CNS regions; activation influences appetite, energy expenditure, and sexual behavior.[15]
• MC5R: widely expressed in exocrine glands and other tissues; involved in exocrine secretion and possibly immune modulation.[15]

MT‑II displays limited selectivity among these receptors and is often described as a non‑selective melanocortin agonist with potent activity at MC3R/MC4R, which underlies its CNS effects including anorexia and pro‑sexual responses.[15]

Intracellular signaling

Upon binding to melanocortin receptors, MT‑II primarily activates Gs‑coupled signaling, leading to:

• increased adenylyl cyclase activity
• elevated intracellular cAMP
• activation of protein kinase A (PKA)
• downstream phosphorylation of transcription factors such as CREB, and in melanocytes, upregulation of MITF and melanogenic enzymes (e.g., tyrosinase).[13][15]

At MC4R and MC3R in the CNS, this cAMP/PKA signaling modulates neuronal circuits governing satiety, stress responses, and sexual behavior.[15]

Evidence summary

Preclinical studies

1. Stress and depression‑related behavior

A 2025 rat study evaluated the antidepressant‑like and antistress effects of MT‑II and the ACTH(4–10) analog Semax in a chronic unpredictable stress (CUS) model.[9] Adult male Sprague–Dawley rats received daily intraperitoneal injections of MT‑II at 60 nmol/kg or saline.[9]

• Sample size: not clearly specified in the abstract, but groups included stressed and non‑stressed animals receiving vehicle or peptide treatments.[9]
• Outcomes:
  • MT‑II attenuated CUS‑induced anhedonia (improved sucrose preference), prevented suppression of body‑weight gain, and reduced adrenal hypertrophy.[9]
  • MT‑II normalized decreased hippocampal brain‑derived neurotrophic factor (BDNF) levels induced by stress.[9]
  • No significant effect on immobility time in the forced swim test was reported.[9]

These results suggest central melanocortin signaling via MT‑II can modulate stress‑induced behavioral and neuroendocrine alterations in rodents, although translational relevance to human depression remains unproven.

2. Analytical and ADME characterization

A 2020 mass spectrometry study used MT‑II as a tool peptide to demonstrate combined MALDI mass spectrometry imaging (MALDI‑MSI) and droplet‑based surface sampling LC‑HRMS for in vivo tissue distribution and metabolite profiling of cyclic peptides in rats.[1]

• MT‑II was administered to animals (dose and route described in the full text), and MALDI‑MSI mapped its distribution and metabolites in tissues.[1]
• The study highlighted metabolic stability and clearance properties of MT‑II as representative of cyclic therapeutic peptides, showing detectable intact peptide and metabolites in multiple organs.[1]

This work provides methodological insights into MT‑II pharmacokinetics but is not focused on therapeutic outcomes.

3. Synthetic chemistry and structural optimization

The first preparative solution‑phase synthesis of MT‑II was reported in 2008, achieving a 12‑step route via a side chain‑to‑side chain cyclization between the ε‑amino of Lys and γ‑carboxylate of Asp, followed by N‑terminal acetyl‑norleucine addition.[11][12]

• Overall yield: 2.6% with >90% purity without preparative chromatography.[11][12]
• The work confirmed the feasibility of scalable MT‑II production and informed synthetic approaches for related cyclic melanocortin analogs.[11][12]

Human clinical data

Peer‑reviewed, formal clinical trials of MT‑II in humans are limited, and much of the reported human use has occurred outside regulated clinical development, including cosmetic “tanning” and sexual enhancement contexts. Robust trial‑level data on dosing, efficacy, and safety—comparable to afamelanotide—are not available in the contemporary clinical trial registries or major regulatory submissions.

Isolated early phase investigations (often cited in secondary literature) explored MT‑II for male erectile dysfunction and photoprotective tanning, but detailed peer‑reviewed reports with sample sizes and standardized outcomes are sparse. In contrast, afamelanotide and other selective MC4R agonists (e.g., bremelanotide) have undergone comprehensive clinical programs; MT‑II is largely considered an experimental precursor within this class.[15]

Clinical and research uses

Established clinical indications

There are no approved therapeutic indications for Melanotan II in the United States, European Union, or other major regulatory jurisdictions.[15]

Investigational and research applications

• Pigmentation and photoprotection: MT‑II has been used experimentally to induce cutaneous hyperpigmentation by activating MC1R on melanocytes, leading to increased eumelanin production, with the conceptual goal of augmenting photoprotection.[13][15] Afamelanotide superseded MT‑II in formal photoprotection trials.
• Sexual dysfunction: Early exploratory work indicated that MT‑II could induce penile erections via central MC3R/MC4R activation, prompting development of more selective derivatives such as bremelanotide (PT‑141). MT‑II itself did not advance to regulatory approval.[15]
• Metabolic and CNS research: In animals, MT‑II is widely used as a pharmacologic probe of melanocortin signaling in appetite suppression, energy balance, stress responses, and mood regulation.[9][15]
• Analytical method development: MT‑II is used as a model cyclic peptide in analytical chemistry and ADME method development, as demonstrated by MALDI‑MSI and LMJ‑SSP‑LC‑HRMS studies.[1]

Non‑medical / off‑label contexts

Despite the lack of approval, MT‑II has been marketed in some settings as an unregulated “tanning peptide” and for sexual enhancement. These uses occur outside formal medical supervision and are not supported by controlled clinical trials. Regulatory agencies have issued warnings regarding such products, emphasizing the absence of quality control and safety evaluation.[15]

Dosing context

No standardized, regulator‑endorsed dosing regimen exists for MT‑II. Available dosing information comes from preclinical studies and limited early‑phase or anecdotal human use; it should not be interpreted as prescribing guidance.

• Animal studies: In the CUS rat model, MT‑II was given intraperitoneally at 60 nmol/kg once daily, which produced measurable behavioral and endocrine effects.[9]
• Pharmacokinetic/ADME work: In the mass spectrometry imaging study, MT‑II was administered systemically (details in the full text) to characterize tissue distribution and metabolism.[1]

Human experimental use has generally involved parenteral administration (subcutaneous or intranasal) at microgram‑level doses, but robust published dosing data with safety and exposure‑response characterization are limited and inconsistent. As such, no evidence‑based therapeutic dosing recommendations can be made.

Safety profile

Adverse effects (inferred from class and limited data)

Systematic safety data for MT‑II are incomplete. However, adverse effects can be inferred from limited reports and from related melanocortin agonists:[15]

• Cutaneous:
  • diffuse hyperpigmentation and increased tanning
  • darkening or new appearance of melanocytic naevi, raising concern about melanoma risk in susceptible individuals (primarily reported with unregulated cosmetic use of melanocortin peptides).
• Gastrointestinal:
  • nausea, vomiting
  • abdominal discomfort.
• Cardiovascular/autonomic:
  • transient flushing, facial warmth
  • possible blood pressure changes and tachycardia, particularly with central melanocortin receptor activation.
• Central nervous system:
  • decreased appetite (anorectic effect)
  • fatigue or malaise in some users
  • headache.
• Sexual function:
  • spontaneous or prolonged erections in males, reflecting MC4R‑mediated pro‑erectile activity; this has been exploited in derivative drugs like bremelanotide.[15]

Preclinical data from the CUS rat study did not report overt toxicity at 60 nmol/kg, but the focus was behavioral and endocrine endpoints, not formal toxicology.[9] The analytical distribution study primarily characterized exposure and metabolites and did not report detailed toxicity findings.[1]

Long‑term safety and carcinogenicity

Long‑term safety, including carcinogenicity and melanoma risk, has not been systematically evaluated for MT‑II in controlled human studies. Concerns arise from:

• biologic plausibility that chronic MC1R activation and increased melanogenesis could affect melanocytic neoplasia risk
• anecdotal reports of changes in moles and pigmented lesions among cosmetic users.

Due to absent formal studies, the magnitude of any such risk remains uncertain.

Contraindications and cautions (conceptual)

Formal contraindication labels do not exist for MT‑II because it is not an approved medicine. Based on mechanism and class effects, theoretical high‑risk groups include:

• individuals with a history of melanoma or dysplastic nevus syndrome
• patients with uncontrolled cardiovascular disease, given potential hemodynamic effects
• pregnant or breastfeeding women, due to lack of reproductive toxicology data
• children and adolescents, given absent pediatric safety data.

These considerations are extrapolated from mechanistic reasoning and related melanocortin agents rather than MT‑II‑specific regulatory guidance.

Regulatory status

• United States: Melanotan II is not approved by the FDA for any indication. The FDA has previously warned against unapproved injectable “tanning” products, including melanocortin analogs, noting lack of evaluation for safety, effectiveness, and quality.[15]
• European Union: MT‑II is not authorized by the EMA. The only melanocortin analog approved in the EU for a pigmentation‑related indication is afamelanotide (SCENESSE) for erythropoietic protoporphyria; MT‑II is not part of that authorization.[15]
• Other regions: No major regulatory authority has granted marketing authorization for MT‑II as a medicinal product. Commercial availability is largely confined to unregulated or gray‑market channels, often as “research chemicals” or cosmetic injectables, which are not subject to standard pharmaceutical oversight.

Accordingly, MT‑II should be regarded as an experimental melanocortin agonist and research tool, with limited controlled human data, an incompletely characterized safety profile, and no recognized therapeutic indication in US/EU regulatory frameworks.[15]